RAB5A and Dravet syndrome: In those studies [132,133] we and our collaborators showed that blocking Rab5 over-activation with a selective p38α inhibitor [37,134] rescued Rab5-positive-endosomal enlargement and cholinergic neurodegeneration in a mouse model of DS (Ts2) as effectively as reversing elevated APP-β-CTF levels [77].